Genome‐Wide CRISPR‐Cas9 Screening Identifies NF‐κB/E2F6 Responsible for EGFRvIII‐Associated Temozolomide Resistance in Glioblastoma

Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy

(2019) Lei Han et al.   ADVANCED MATERIALS

The role of PTRF/Cavin1 as a biomarker in both glioma and serum exosomes

(2018) Kai Huang et al.   Theranostics

The REMBRANDT study, a large collection of genomic data from brain cancer patients

(2018) Yuriy Gusev et al.   Scientific Data

E2F6 Functions as a Competing Endogenous RNA, and Transcriptional Repressor, to Promote Ovarian Cancer Stemness

(2018) Frank H.C. Cheng et al.   CANCER SCIENCE

MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway

(2017) Bai-Sheng Huang et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells

(2016) Monika Paul-Samojedny et al.   BIODRUGS

FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways

(2016) YiHan Wu et al.   BIOMEDICINE & PHARMACOTHERAPY

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

(2016) Michele Ceccarelli et al.   CELL

The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells

(2015) Fangyong Dong et al.   NEURO-ONCOLOGY

Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy

(2015) Kirk E. Cahill et al.   NEURO-ONCOLOGY

RNA-seq of 272 gliomas revealed a novel, recurrentPTPRZ1-METfusion transcript in secondary glioblastomas

(2014) Zhao-Shi Bao et al.   GENOME RESEARCH

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Chk1 Inhibits E2F6 Repressor Function in Response to Replication Stress to Maintain Cell-Cycle Transcription

(2013) Cosetta Bertoli et al.   CURRENT BIOLOGY

Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy

(2013) Michael Weller et al.   INTERNATIONAL JOURNAL OF CANCER

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

(2013) Ophir Shalem et al.   SCIENCE

E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression

(2012) L. A. Carvajal et al.   GENES & DEVELOPMENT

NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug

(2012) Simona Caporali et al.   Journal of Translational Medicine

Standards of care for treatment of recurrent glioblastoma—are we there yet?

(2012) Michael Weller et al.   NEURO-ONCOLOGY

Nuclear initiated NF-κB signaling: NEMO and ATM take center stage

(2010) Shigeki Miyamoto   CELL RESEARCH

EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma

(2009) B. Mukherjee et al.   CANCER RESEARCH

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma

(2008) J. N. Sarkaria et al.   CLINICAL CANCER RESEARCH

DNA-damage response control of E2F7 and E2F8

(2008) L Panagiotis Zalmas et al.   EMBO REPORTS